Table S1. Characteristics of eligible studies evaluating BRCA1 level and clinical outcome.
| Lead author [Y] (ref.) | Tumor type | No. of patients | Median age | Patient | Stage | Chemotherapyregimen | BRCA1 detection | Antibody | Assessment | Evaluation | Cut off | BRCA1 | CR + PR | SD + PD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zimling [2012] (6) | Malignant pleural | 49 | 64 | Europe | I-IV | Vinorelbine 25 mg m−2 i.v. weekly and cisplatin100 mg i.v. every 4 weeks | IHC | Mousemonoclonal anti-human BRCA1 | H-score | Positive: H-score ≥ upper quartile; Negative: H-score < upper quartile | Negative | 10 | 16 | |
| Mesothelioma | Positive | 5 | 11 | |||||||||||
| Gao [2013] (14) | Esophageal | 45 | 62 | Asian | II-IV | Docetaxel (60–75 mg/m2) plus 5-fluorouracil (500 mg/m2, D1, D5) | qPCR | Using a cut off value of 11.96 | Low | 6 | 17 | |||
| Squamous cell | High | 12 | 10 | |||||||||||
| Carcinoma | ||||||||||||||
| Papadaki [2011] (15) | NSCLC | 131 | 60 | Europe | IIIB-IV | Docetaxel cisplatin; docetaxel gemcitabine | cDNA quantification | Median value | Low | 13 | 53 | |||
| High | 27 | 38 | ||||||||||||
| Su [2011] (16) | NSCLC | 85 | 60 | Asian | IIIB-IV | Cisplatin (75 mg/m2) or carboplatin (AUC =5) pius vinorelbine (25 mg/m2, D1, D8) orpaclitaxe (175 mg/m2) | Real-time PCR | The median expression levels (10.11×10−2) | Low | 8 | 21 | |||
| High | 28 | 28 | ||||||||||||
| Kim [2005] (17) | Breast cancer | 60 | NA | Asian | Docetaxel (60mg/m2, q3w), four cycles unless progressive disease | IHC | Ab-1 (MS110) provider: oncogene (Cambridge, MA) | According to the previous reports (10%) | Low | 5 | 9 | |||
| High | 9 | 37 | ||||||||||||
| Kurebayashi [2006] (18) | Breast cancer | 19 | 58 | Asian | Primary | 13 patients received taxane (docetaxel or paclitaxel) alone, 3 patients taxane with medroxyprogesterone | IHC | Rabbit polyclonal, Ab-1,Oncogene, Boston, MA, USA | 10% of the tumor cells | Absence | 4 | 9 | ||
| Present | 1 | 5 | ||||||||||||
| Acetate, 2 patients taxane with pamidronate and one taxane with trastuzumab | ||||||||||||||
| Zhao [2014] (19) | SCLC | 158 | 59 | Asian | IIIB-IV | Cisplatin (75 mg/m2, D1) or carboplatin (AUC =5, D1) plus gemcitabine (1,000 mg/m2, D1, D8), vinorelbine (30 mg/m2, D1, D8) or paclitaxel (175 mg/m2, D1) | Fluorescence-based, real-time detection method | The median expression levels (4.3) | Low | 9 | 54 | |||
| High | 24 | 71 | ||||||||||||
| Wan [2011] (20) | Breast cancer | 87 | NA | Asian | IIIB-IV | Taxanes (150 mg/ m2, D1) plus cisplatin (25mg/m2, D1-3) | IHC | Mouse anti-BRCA1; monoclonal antibody (ZHGB BIO, China) | According to the previous studies, positive≥10% of the tumor cells negative<10% of the tumor cells | Low | 23 | 22 | ||
| High | 17 | 25 | ||||||||||||
| Boukovinas [2008] (7) | NSCLC | 95 | 60 | Europe | IIIB-IV | Gemcitabine (1,000 mg/m2, D1, D8)plus docetaxel (100 mg/m2 D8) | PCR | Median mRNA expression levels (3.64) | Low | 12 | 51 | |||
| High | 17 | 15 | ||||||||||||
| Lesnock [2013] (21) | Ovarian cancer | 393 | NA | White black and other | I-III | Intravenous paclitaxel and cisplatin or combination of intravenous paclitaxel and intraperitoneal cisplatin and paclitaxel | IHC | MS110 clone; monoclonal antibody Ab-1 (Oncotech Inc., Tustin, CA, USA) | Low BRCA1 expression: <10% staining; normal:>10% staining | |||||
| Weberpals [2011] (22) | Ovarian carcinoma | 116 | 57 | Europe | II-IV | Cisplatin plus topotecan followed by paclitaxel plus carboplatin or carboplatin plus paclitaxel | IHC | Mouse monoclonal BRCA1 antibody (MS110, Calbiochem, Darmstadt, Germany) | BRCA1 was 2.5 | |||||
| Papadaki [2012] (23) | NSCLC | 100 | 63 | Europe | IV | Docetaxel/gemcitabine or vinorelbine/gemcitabine | Relative cDNA quantification | Median mRNA expression levels (4.28) | ||||||
| Wei [2011] (24) | Gastric cancer | 152 | 58 | Asian | III-IV | Docetaxel-based | q-PCR | Cut-off point for BRCA1 was 4.6 |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; IHC, Immunohistochemistry; qPCR, real-time polymerase chain reaction; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; BRCA1, breast cancer susceptibility gene 1.